Crossing the finish line towards a disease-modifying treatment for Angelman syndrome

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Recent progress in the development of genetic therapies promises that impactful treatments for single-gene neurodevelopmental disorders are imminent. But can derailed neurodevelopmental processes be mended after broken genes are replaced or otherwise restored? The results of ongoing clinical trials for Angelman syndrome will soon yield answers to this pressing question, yet the trials face significant obstacles. Here we identify insights needed to aid the quest for a disease-modifying Angelman syndrome therapy, which could serve as a roadmap for the expeditious development of genetic therapies for other single-gene neurodevelopmental disorders.
Funding Information
  • Angelman Syndrome Foundation
  • Angelman Syndrome Alliance

This publication has 49 references indexed in Scilit: